By Daniella Parra
The nascent psychotropic industry didn’t exist five years ago and many companies have been hampered by toxic capital structures that have allowed developmental companies to get funded.
“I believe with the right market conditions, capital markets experience, and a disciplined approach, there are many opportunities that exist,” Mr. Nanula said. “For example, we recently made an offer to purchase Pasithea Therapeutics (Nasdaq: KTTA), and believe their shareholders would benefit from the offer as would the shareholders of Lucy.”
When asked about his experience translates to his leadership with Lucy, Mr. Nanula said he looks forward to the challenges and new business markets.
“When I joined Disney, I knew nothing about theme parks, nor did I know much about biotech or hotels when I joined Amgen or Starwood,” Mr. Nanula said. “But I have always enjoyed the challenge of learning a business and the specific challenges that exist within a specific sector and trying to solve for them.”